Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

PHASE1CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

February 21, 2019

Study Completion Date

February 21, 2019

Conditions
Non-Hodgkin LymphomaBurkitt's LymphomaChronic Lymphocytic LeukemiaLymphoma, Large B-Cell, DiffuseLymphoma, FollicularLymphoma, Mantle-CellLymphoma, Marginal ZoneWaldenstrom MacroglobulinemiaPrimary Mediastinal B-cell Lymphoma
Interventions
DRUG

ADCT-402

intravenous infusion

Trial Locations (11)

10032

Columbia University Medical Center Herbert Irving Pavilion, New York

29605

Greenville Health System, Institute for Translational Oncology Research, Clinical Research Unit, Greenville

30322

Winship Cancer Institute of Emory University, Atlanta

30342

Blood and Marrow Transplant Group of Georgia, Atlanta

44106

University Hospitals of Cleveland, Cleveland

53226

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

63110

Washington University School of Medicine, St Louis

92093

UC San Diego Moores Cancer Center, La Jolla

Unknown

U.O Oncologia e Ematologia - Istituto Clinico Humanitas, Milan

NW1 2BU

University College London Hospitals, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

Sponsors
All Listed Sponsors
lead

ADC Therapeutics S.A.

INDUSTRY